Almada, Portugal Clinical Trials

Research Site

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

1160.136.17005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

GSK Investigational Site

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Research Site Updated

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Hospital Garcia de Orta

Clinical Status Monitoring in Implantable Cardiac Defibrillator (ICD) Patients by Physiological Diagnosis (PhD) Function

Research Site

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Research Site

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Research Site

ATLAS - Anti-Tweak in Lupus Nephritis Patients

GSK Investigational Site

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

GSK Investigational Site

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Research Site

ATLAS - Anti-Tweak in Lupus Nephritis Patients

Research Site Updated

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Research Site

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

1160.136.17005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Research Site

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

GSK Investigational Site

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects